Gianluca Pirozzi

Gianluca Pirozzi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Gianluca Pirozzi sits on this spectrum.

Gianluca Pirozzi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Gianluca Pirozzi sits on this spectrum.

Best Publications

• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

  Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck

  2113
  Citations

• Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

  Mario Castro;Jonathan Corren;Ian D. Pavord;Jorge Maspero

  1930
  Citations

• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  1539
  Citations

• Dupilumab in persistent asthma with elevated eosinophil levels.

  Sally Wenzel;Linda Ford;David Pearlman;Sheldon Spector

  1501
  Citations

• Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

  Claus Bachert;Claus Bachert;Joseph K Han;Martin Desrosiers;Peter W Hellings

  1450
  Citations

• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  1357
  Citations

• Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

  Klaus F. Rabe;Parameswaran Nair;Guy Brusselle;Jorge F. Maspero

  1152
  Citations

• Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

  Sally Wenzel;Mario Castro;Jonathan Corren;Jorge Maspero

  1086
  Citations

• Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

  Claus Bachert;Claus Bachert;Leda Mannent;Robert M Naclerio;Joaquim Mullol

  849
  Citations

• Targeting key proximal drivers of type 2 inflammation in disease

  Namita A. Gandhi;Brandy L. Bennett;Neil M. H. Graham;Gianluca Pirozzi

  779
  Citations

• Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

  Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  719
  Citations

• Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

  Emma Guttman-Yassky;Emma Guttman-Yassky;Robert Bissonnette;Benjamin Ungar;Benjamin Ungar;Mayte Suárez-Fariñas

  661
  Citations

• Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

  Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  528
  Citations

• Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

  M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  523
  Citations

• Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

  Jennifer D. Hamilton;Mayte Suárez-Fariñas;Nikhil Dhingra;Irma Cardinale

  518
  Citations

• Commonality of the IL-4/IL-13 pathway in atopic diseases

  Namita A. Gandhi;Gianluca Pirozzi;Neil M. H. Graham

  501
  Citations

• Conjunctivitis in dupilumab clinical trials.

  B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  423
  Citations

• Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

  Eric L. Simpson;Thomas Bieber;Laurent Eckert;Richard Wu

  345
  Citations

• Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.

  G. Yosipovitch;M. Reaney;V. Mastey;L. Eckert

  330
  Citations

• Dupilumab Shows Long-Term Safety and Efficacy in Patients With Moderate to Severe Atopic Dermatitis Enrolled in a Phase 3 Open-Label Extension Study

  Mette Deleuran;Diamant Thaçi;Lisa A. Beck;Marjolein de Bruin-Weller

  246
  Citations